adenocarcinoma of prostate

Investigate the Treatment of Incidental Adenocarcinoma of Prostate ( Report of 28 Cases )

偶发前列腺癌的临床治疗探讨（附28例报告）

Incidental adenocarcinoma of prostate report of 12 cases

前列腺偶发癌12例报告

Basal cell adenocarcinoma of prostate

前列腺基底细胞腺癌

Prostate specific antigen density DPSA was studied in 11 cases of incidental adenocarcinoma of prostate and 20 cases of benign prostatic hyperplasia ( BPH ) .

为探讨前列腺偶发癌早期诊断的有效指标，对11例前列腺偶发癌和20例前列腺增生症（BPH）患者前列腺特异性抗原密度（DPSA）进行了检测。

Results The mean PSA in incidental adenocarcinoma of prostate group and BPH group were ( 5.03 ± 1.61 ) and ( 4.31 ± 1.52 ) , respectively , with no statistic difference ( P < 0.01 ) .

结果前列腺偶发癌组和BPH组PSA分别为（5.03±1.61）、（4.31±1.52）μg/L，差异无显著性（P>0.05）；

Purpose To investigate the pathologic differential diagnosis between sclerosing adenosis and adenocarcinoma of the prostate .

目的探讨前列腺硬化性腺病与小腺泡结构前列腺癌的病理鉴别诊断。

The incidence and mortality of adenocarcinoma of the prostate continue to rise and will continue to pose a major public health problem .

前列腺癌（Pca）发病率的持续增长和死亡率的增加是近年来困扰大家的一个公众问题。

Methods One hundred and thirty-six patients with adenocarcinoma of the prostate were treated with combined androgen block ( orchiectomy and flutamide 250 mg , Tid ) .

方法136例前列腺癌患者采用联合雄激素阻断治疗（睾丸切除+氟他胺或福至尔，250mg/次，3次/d）。